AN2 Therapeutics Inc
an2therapeutics.comWhat Do They Do?
Develops boron-based small-molecule drug candidates for hematologic diseases, infectious diseases, and cancer.
10-K for FY2025, filed Mar 17, 2026
How Are They Changing?
Broader disease focus
The earlier report centered on epetraborole for NTM lung disease and other infectious diseases; the latest report also describes programs for hematologic diseases and oncology alongside infectious-disease programs.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 17, 2026AN2 Therapeutics, Inc. is a Delaware corporation incorporated on February 24, 2017. We launched operations in November 2019. We are a…View ↗
We believe our boron chemistry platform has the potential to address biological targets that have been difficult to inhibit using molecules…View ↗
In addition to our NTM development programs for epetraborole, we intend to pursue epetraborole and other compounds for global health…View ↗
We are a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived…View ↗
We are pursuing a number of oncology targets where we believe our boron chemistry may offer a competitive advantage in terms of…View ↗
Our global health strategy focuses on leveraging our proprietary boron chemistry platform to develop treatments for infectious diseases…View ↗
Loading...
